These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30383490)

  • 1. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
    Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
    Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
    Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
    J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
    Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
    Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
    Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
    J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
    Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
    Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome.
    Tessaris D; Matarazzo P; Lala R; Defabianis P
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):333-6. PubMed ID: 26565547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
    Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
    J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
    van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
    Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
    Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.
    Thomsen MD; Rejnmark L
    Calcif Tissue Int; 2014 Apr; 94(4):384-95. PubMed ID: 24390518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for the treatment of fibrous dysplasia of bone.
    Chapurlat R; Legrand MA
    Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
    Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
    Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
    Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.
    Hagelstein-Rotman M; Appelman-Dijkstra NM; Boyce AM; Chapurlat R; Dur NBJ; Gensburger D; Majoor BCJ; van de Sande MAJ; Dijkstra PDS
    Calcif Tissue Int; 2022 Mar; 110(3):334-340. PubMed ID: 34854944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India.
    Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N
    Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothyroidism in McCune-Albright Syndrome and Role of Bone Scan in Management of Fibrous Dysplasia: An Unusual Case Scenario with Review of Literature.
    Kumar N; Kheruka SC; Singh RK; Ravina M; Dutta D; Gambhir S
    Indian J Nucl Med; 2017; 32(1):25-29. PubMed ID: 28242980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
    Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
    Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.
    Akintoye SO; Boyce AM; Collins MT
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):e149-55. PubMed ID: 23953425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.
    Nadella S; Mupparapu M; Akintoye SO
    Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
    Pfeilschifter J; Ziegler R
    Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.